4.365USD-7.13%Mkt Cap: 346.92M USDP/E: —Last update: 2026-06-01
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the re…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap346.92M USD
Enterprise Value118.35M USD
Revenue (TTM)—
Gross Profit-159.32M USD
Net Income (TTM)-158.35M USD
Revenue/Share—
Last Price4.365 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees55
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.37
PEG—
EV/EBITDA-0.63
EV/Revenue—
P/S—
P/B1.60
EPS (TTM)-2.11
EPS (Forward)-1.39
52W Range
2.78043% of range6.450
52W High6.450 USD
52W Low2.780 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-57.49%
ROA-50.23%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-132.03M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-25.28%
Net Debt-255.37M USD
Net Debt/EBITDA1.35
Balance Sheet
Debt/Equity0.00
Current Ratio7.89
Quick Ratio7.67
Book Value/Sh2.920 USD
Cash/Share3.199 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.7 (Buy)
Target (Mean)8.667 USD
Target Range6.000 USD – 10.00 USD
# Analysts3
Ownership
Shares Out.80.03M
Float60.24M
Insiders13.40%
Institutions80.15%
Short Interest
Short Ratio23.5d
Short % Float12.24%
Short % Out.9.49%
Shares Short7.59M
Short (prev mo.)7.69M
Technical
SMA 505.327 (-18.1%)
SMA 2004.046 (+7.9%)
Beta0.38
S&P 52W Chg27.94%
Avg Vol (30d)302.64K
Avg Vol (10d)367.87K
Technical Indicators
RSI (14)44.3
MACD-0.2535
MACD Signal-0.2814
MACD Hist.+0.0279
BB Upper6.082 USD
BB Middle4.849 USD
BB Lower3.617 USD
BB Width50.83%
ATR (14)0.2578 USD
Vol Ratio (20d)0.52x